HCM Stock: Price, Earnings History and SEC Filings
HUTCHMED (China) Limited (HCM) last traded at $13.15, down 3.24% on the latest session and down 10.1% over the past month.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HCM earnings history
Earnings history is not available right now.
Latest SEC filings for HCM
Insider filing activity
HCM insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
HCM news
- 3 British Healthcare Stocks To Own In October 2026Oct 31, 2026 · finance.yahoo.com
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune ThrombocytopeniaOct 29, 2026 · finance.yahoo.com
- Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung CancerOct 27, 2026 · finance.yahoo.com
- HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026Oct 26, 2026 · finance.yahoo.com
- HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of MedicineOct 26, 2026 · finance.yahoo.com
- What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For ShareholdersOct 25, 2026 · finance.yahoo.com
- HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued?Oct 23, 2026 · finance.yahoo.com
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside ChinaOct 21, 2026 · finance.yahoo.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited (HCM) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Cayman Islands.